Latent TB Testing Market to Hit USD 773.4 Million by 2029 with 5.8% CAGR | MarketsandMarkets Trademark

The key players in this market are QIAGEN (Netherlands), Revvity (US), Beijing Wantai Biopharmaceutical Co., Ltd. (China), Sanofi (France), Endo, Inc. (US), bioMerieux (France), SD Biosensor, INC. (South Korea), Lionex GmbH (Germany), invitros (South Korea), Serum Institute of India Pvt. Ltd. (India)
The global [https://www.marketsandmarkets.com/Market-Reports/latent-tb-testing-market-125200332.html?utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=latenttbtestingmarket] is expected to grow to USD 773.4 Million by 2029, up from USD 582.5 Million in 2024, at a CAGR of 5.8% over the forecast period. The latent TB testing market is expanding due to the growing incidence of tuberculosis worldwide and the increasing need for early detection as well as preventive interventions. The traditional tuberculin skin tests have limitations, and the problem of false positives increases with the widespread use of BCG vaccination, which has fueled the increased use of more precise diagnostics such as interferon gamma release assays (IGRAs). This is coupled with the increasing TB elimination programs led by governments, public health initiatives, and the intensified further demand for adequate testing methods in high-burden countries. Increased awareness among healthcare providers and the increased risk groups, such as people living with immunodeficiency diseases, for example, individuals with HIV, increases the need for better diagnostics. Increased financial and regulatory support also makes these diagnostics more accessible to the general population. All these factors promote steady growth in the latent TB testing market.

Download PDF Brochure: [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=125200332&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=latenttbtestingmarket]

Browse in-depth TOC on "Latent TB Testing Market"

270 - Tables

46 - Figures

262 - Pages

A significant technological shift which could redefine the business landscape in the latent TB testing market, is the growing interest in developing and refining IGRA tests. IGRA presents more significant advantages than tuberculin skin tests because these are more accurate and sensitive, especially for populations immunized with BCG vaccine. As the global healthcare systems advance towards precision diagnostics, the need for IGRAs is also on the rise because these tests are more sensitive and specific and can be completed in a single patient visit. In addition, advancements in the IGRA test platforms, such as automation, continue to make tests more accessible and scalable for deployment in both high-burden and resource-limited settings. This shift will, therefore, lead towards greater market growth driven by more reliable, faster, and easier use of testing methods and the entry of new players to the market and existing companies to invest much heavily in IGRA technology.

In 2023, the people living with HIV segment dominated the latent TB testing market by application segment.

Based on application, the latent TB testing market is segmented into household contacts with pulmonary TB, people living with HIV, and other applications. The people living with HIV segment dominated the largest share of the global latent TB testing market in 2023. People suffering from HIV have compromised immune systems and hence are at an extremely increased risk of infections caused by latent TB. Routine screening and early detection thus become crucial for them. Global health initiatives and strategic efforts are also being undertaken towards integrated care focused on TB testing among PLHIV. In this regard, identification of latent infections before these become active forms of TB prevents the further complications of resulting TB and reducing mortality rates. Additionally, introduction of new products and approvals of more advanced tests for TB has made the test procedures easier, which in turn increases their usage among the high-risk population.

In 2023, the largest end-user segment of the latent TB testing market was diagnostic laboratories.

Categorized by end user, the latent TB testing market is segmented into diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users. The largest share of the latent TB testing market was held by the diagnostic laboratories segment in 2023. As the number of tuberculosis cases increases globally, diagnostic laboratories play a critical role in ensuring accurate results for the diagnostic tests, hence ensuring proper management and treatment of latent TB. With the implementation of quality control measures and standardized procedures in diagnostic laboratories, there will be a guarantee of the validity and accuracy of test results. Moreover, heightened awareness about the threat of latent TB, especially among specific vulnerable groups, has led to the increase in the number of tests undertaken at such centers. Therefore, these factors contribute to the dominance of diagnostic laboratories in the latent TB testing market.

North America is the largest regional market for latent TB testing.

The market for latent TB testing has been divided into five key geographical regions, namely North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2023, North America held the predominant portion of the latent TB testing market. The latent TB testing market in North America is the biggest regional market, mainly due to several key factors, such as an established healthcare infrastructure across the region and the extensive availability of advanced diagnostic tools, like interferon gamma release assays, that are highly sensitive and convenient to use. Moreover, government initiatives and the control programs for TB prevailing in the US and Canada, which strongly emphasize on early detection and preventive care also stimulate the demand for latent TB tests. The growing vulnerable population, especially immunocompromised patients and healthcare workers, increases the necessity for TB-specific diagnostics. In addition, a higher level of public awareness on prevention of TB and increased public health investment are likely to maintain North America as the dominant regional market.

Request Sample Pages : [https://www.marketsandmarkets.com/requestsampleNew.asp?id=125200332&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=latenttbtestingmarket]

The key players in this market are QIAGEN (Netherlands), Revvity (US), Beijing Wantai Biopharmaceutical Co., Ltd. (China), Sanofi (France), Endo, Inc. (US), bioMerieux (France), SD Biosensor, INC. (South Korea), Lionex GmbH (Germany), Serum Institute of India Pvt. Ltd. (India), ARKRAY, Inc. (Japan), Zhi Fei Biological (China), AID Autoimmun Diagnostika GmbH (Germany), Boditech Med Inc. (South Korea), Bioneovan Co., Ltd (China), and Biopanda Reagents Ltd (UK). The market players have adopted various strategies such as development of advanced products, partnerships, expansions, and acquisitions to strengthen their position in the latent TB testing market. The organic and inorganic strategies have helped the market players expand globally by providing advanced latent TB tests.

QIAGEN is an innovator of sample technologies. The company provides product ranges for the isolation of genomic and viral nucleic acids, DNA cleanup after PCR, sequencing, and library preparation in sequencing applications. The company's significant global presence gives it a robust platform to enhance penetration in emerging markets and global reach in more geographies. It also maintains this competitive advantage with dynamic research and development activities ascribed to effective supply chain management. The company also adopts several organic growth strategies, including the introduction of new products and obtaining relevant regulatory approvals. For instance, in February 2023, QIAGEN's QuantiFERON-TB Gold Plus tuberculosis blood test received the CE-marking in the European Union under its 2017/746 In Vitro Diagnostic Medical Devices Regulation (IVDR). Such strategic steps of the company have helped the company to maintain continuous leadership in the latent TB testing market.

Revity is a leader in health science solutions, technologies, expertise, and services that work within more specialized lines such as translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and more. It has a large distribution network in North America, Europe, Asia Pacific, and Latin America, Middle East & Africa that facilitates the company to enhance its global supply chain that will enable them for sustainability in offering their services. The company has made heavy investments in research and development in pursuing continuous innovation and product development. The company also focuses on long-term value creation, organic growth opportunities, and strategic investments in the growth strategy through the diversification of its capabilities along with improving the customer experience. The company adopts organic strategies that cover product launches and acquiring regulatory approvals to sustain its presence in the market.

Beijing Wantai Biopharmaceutical Co., Ltd. is among the leading manufacturers of diagnostics for infectious diseases in China and a global leader in the diagnosis of Hepatitis E. Other diagnostic tests developed by the company include but are not limited to ELISA, rapid tests, PCR, CLIA, and confirmation tests. With strong and focused R&D under its wing, the company is specialized in enzyme immunoassay, chemiluminescence, nucleic acid diagnosis, and producing monoclonal/polyclonal antibody. Its eminent presence in the diagnostics industry comes strongly from leading national research initiatives and rapid commercialization of innovative scientific research. These strengths have played a significant role in enabling the company to achieve a prominent position in the latent TB testing market.

For more information, [https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=125200332&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=latenttbtestingmarket]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=latent-tb-testing-market-to-hit-usd-7734-million-by-2029-with-58-cagr-marketsandmarkets]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/latent-tb-testing-market-125200332.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.